Gynecology

The Two Pathways: HPV-Associated vs. HPV-Independent VIN

At a Glance

Vulvar intraepithelial neoplasia (VIN) has two distinct types. HPV-associated VIN (vHSIL) is driven by the HPV virus and typically progresses slowly. HPV-independent VIN (dVIN) is linked to chronic skin conditions like lichen sclerosus, is more aggressive, and requires prompt surgical treatment.

While all Vulvar Intraepithelial Neoplasia (VIN) involves abnormal cells, doctors now recognize that VIN is not just one disease. Instead, it follows two very different biological “pathways.” Understanding which pathway your condition follows is one of the most critical pieces of information for your care, as it determines how quickly the condition might progress and how aggressively it needs to be treated ^[1]^[2].

Pathway 1: HPV-Associated (uVIN or vHSIL)

This type is caused by a persistent infection with high-risk types of the Human Papillomavirus (HPV). It is most commonly found in younger women or those who smoke ^[3].

How it develops: HPV enters the skin cells and interferes with the cell’s natural “brakes” on growth. This leads to the formation of abnormal lesions that are often multifocal (appearing in several different spots at once) ^[4].
The “p16” Marker: In the lab, pathologists use a stain called p16. In this type of VIN, p16 is usually “block-positive,” meaning it shows up as a strong, continuous band of color under the microscope. This is a hallmark sign of HPV activity ^[1]^[5].
Behavior: While it requires treatment, this type generally progresses to invasive cancer more slowly than the other type. In some cases, it can even be managed with topical creams like imiquimod rather than surgery ^[4]^[6].

Pathway 2: HPV-Independent (dVIN)

This type is not caused by a virus. Instead, it is driven by chronic inflammation and genetic changes. It is more common in older women and is strongly associated with a skin condition called lichen sclerosus ^[7]^[8].

How it develops: Years of chronic irritation (like lichen sclerosus) cause the skin cells to develop mutations in a gene called TP53. This gene is responsible for repairing damaged DNA; when it is mutated, abnormal cells can grow unchecked ^[9]^[10].
The “p53” Marker: Pathologists look for a p53-mutant pattern. This might look like an extreme “over-expression” (too much protein) or a “null” pattern (a complete absence of the protein). Both are signs that the cell’s repair system is broken ^[11]^[12].
Behavior: This type is considered much more aggressive. It has a high “malignant potential,” meaning it is more likely to turn into invasive cancer, and it can do so in a very short amount of time—sometimes in just months ^[13]^[14]. (Note: While this sounds frightening, waiting a few weeks to coordinate your surgery with a specialist is generally safe and expected.)

Why the Distinction Matters

It is vital to know your type because the “rules” of treatment change depending on the pathway:

Feature	HPV-Associated (vHSIL)	HPV-Independent (dVIN)
Primary Cause	HPV infection ^[3]	Chronic inflammation (e.g., Lichen Sclerosus) ^[7]
Typical Lab Markers	p16 positive / p53 “wild-type” ^[1]	p16 negative / p53 “mutant” ^[5]
Progression Risk	Lower / Slower ^[15]	High / Rapid ^[13]
Common Treatment	Creams, laser, or excision ^[4]	Surgical excision is standard ^[16]
Monitoring	Regular check-ups ^[17]	Frequent, lifelong surveillance ^[18]

If your report indicates dVIN, your surgical team will focus heavily on achieving “clear margins”—ensuring that every single abnormal cell is removed—to lower the high risk of the condition returning or becoming invasive cancer ^[16]^[18]. In contrast, for vHSIL, the focus may be more on preserving as much normal tissue as possible while still controlling the disease ^[19].

Return to Home Page

Common questions in this guide

What is the difference between HPV-associated VIN and HPV-independent dVIN?

HPV-associated VIN (vHSIL) is caused by a persistent HPV infection and generally grows slowly. HPV-independent VIN (dVIN) is caused by chronic skin inflammation like lichen sclerosus, progresses much faster, and is considered more aggressive.

What does a 'p16 block-positive' result mean on my VIN pathology report?

A p16 block-positive result is a strong sign that your VIN is caused by an HPV infection. This indicates the HPV-associated pathway (vHSIL), which generally has a lower and slower risk of progressing to cancer compared to the other type.

What does a 'p53-mutant' pattern mean on my VIN pathology report?

A p53-mutant pattern means the abnormal cells have a broken DNA repair system, which is a hallmark of HPV-independent dVIN. This type has a higher risk of turning into invasive cancer quickly and usually requires surgical removal.

Do I need surgery for VIN?

Treatment depends on your specific type of VIN. HPV-associated VIN might be managed with topical creams or laser therapy, while HPV-independent dVIN typically requires strict surgical excision to ensure all abnormal cells are completely removed.

Does lichen sclerosus increase my risk for VIN?

Yes, years of chronic irritation from conditions like lichen sclerosus can lead to genetic changes in the skin cells. This chronic inflammation is the primary driver for HPV-independent dVIN, making careful, lifelong monitoring essential.

Curated prompts to bring to your next appointment.

1.Does my pathology report show a 'p53-mutant' pattern or a 'p53-wild-type' pattern?
2.Was p16 staining performed, and was it 'block-positive'?
3.Given my specific type of VIN, what is the estimated timeline for my next follow-up or treatment?
4.If I have dVIN, are we confident that the surgical margins are completely clear to prevent rapid recurrence?
5.Do I have signs of lichen sclerosus that need to be managed alongside the VIN?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (19)

1
Precursor lesions of vulvar squamous cell carcinoma - histology and biomarkers: A systematic review.
Dasgupta S, Ewing-Graham PC, Swagemakers SMA, et al.
Critical reviews in oncology/hematology 2020; (147()):102866 doi:10.1016/j.critrevonc.2020.102866.
PMID: 32058913
2
p53 and p16 expression profiles in vulvar cancer: a translational analysis by the Arbeitsgemeinschaft Gynäkologische Onkologie Chemo and Radiotherapy in Epithelial Vulvar Cancer study group.
Woelber L, Prieske K, Eulenburg C, et al.
American journal of obstetrics and gynecology 2021; (224(6)):595.e1-595.e11 doi:10.1016/j.ajog.2020.12.1220.
PMID: 33453182
3
Precancerous Squamous Lesions of the Vulva.
Welch KC, Haefner HK, Saunders NA
Obstetrics and gynecology 2025; doi:10.1097/AOG.0000000000006150.
PMID: 41380160
4
Management of Vulvar Cancer Precursors: A Survey of the International Society for the Study of Vulvovaginal Disease.
Green N, Adedipe T, Dmytryshyn J, et al.
Journal of lower genital tract disease 2020; (24(4)):387-391 doi:10.1097/LGT.0000000000000559.
PMID: 32986387
5
High-grade vulvar intraepithelial neoplasia: comprehensive characterization and long-term vulvar carcinoma risk.
Thuijs NB, van Beurden M, Duin S, et al.
Histopathology 2024; (84(2)):301-314 doi:10.1111/his.15050.
PMID: 37726173
6
Topical imiquimod versus surgery for vulvar intraepithelial neoplasia: a multicentre, randomised, phase 3, non-inferiority trial.
Trutnovsky G, Reich O, Joura EA, et al.
Lancet (London, England) 2022; (399(10337)):1790-1798 doi:10.1016/S0140-6736(22)00469-X.
PMID: 35483400
7
[Vulvar intraepithelial neoplasias].
Plantier F
Annales de pathologie 2022; (42(1)):58-67 doi:10.1016/j.annpat.2021.02.014.
PMID: 33744030
8
Risk of Development of Vulvar Cancer in Women With Lichen Sclerosus or Lichen Planus: A Systematic Review.
Vieira-Baptista P, Pérez-López FR, López-Baena MT, et al.
Journal of lower genital tract disease 2022; (26(3)):250-257 doi:10.1097/LGT.0000000000000673.
PMID: 35285455
9
Somatic Mutation Profiling in Premalignant Lesions of Vulvar Squamous Cell Carcinoma.
Zięba S, Pouwer AW, Kowalik A, et al.
International journal of molecular sciences 2020; (21(14)) doi:10.3390/ijms21144880.
PMID: 32664330
10
Clonal Relationship Between Lichen Sclerosus, Differentiated Vulvar Intra-epithelial Neoplasia and Non HPV-related Vulvar Squamous Cell Carcinoma.
Pouwer AW, VAN DEN Einden LCG, VAN DER Linden M, et al.
Cancer genomics & proteomics 2020; (17(2)):151-160 doi:10.21873/cgp.20175.
PMID: 32108037
11
Mass Spectrometry Proteomic Analysis of Four p53 Patterns in Differentiated Vulvar Intraepithelial Neoplasia.
Jamaluddin MFB, Day T, Tanwar PS, et al.
Journal of lower genital tract disease 2023; (27(2)):146-151 doi:10.1097/LGT.0000000000000720.
PMID: 36622249
12
Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome.
Tessier-Cloutier B, Pors J, Thompson E, et al.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2021; (34(2)):508-518 doi:10.1038/s41379-020-00651-3.
PMID: 32792599
13
The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review.
Voss FO, Thuijs NB, Vermeulen RFM, et al.
Cancers 2021; (13(24)) doi:10.3390/cancers13246170.
PMID: 34944788
14
HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course.
McAlpine JN, Kim SY, Akbari A, et al.
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2017; (36(6)):507-516 doi:10.1097/PGP.0000000000000375.
PMID: 28319571
15
Accentuated p53 staining in usual type vulvar dysplasia-A potential diagnostic pitfall.
Jeffreys M, Jeffus SK, Herfs M, Quick CM
Pathology, research and practice 2018; (214(1)):76-79 doi:10.1016/j.prp.2017.11.009.
PMID: 29254796
16
Incidence and Risk Factors for Recurrence and Progression of HPV-Independent Vulvar Intraepithelial Neoplasia.
Voss FO, van Beurden M, Veelders KJ, et al.
Journal of lower genital tract disease 2024; (28(2)):153-159 doi:10.1097/LGT.0000000000000794.
PMID: 38518213
17
Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years.
Bassetty KC, Thomas A, Chandy RG, et al.
Journal of obstetrics and gynaecology of India 2022; (72(Suppl 1)):334-339 doi:10.1007/s13224-022-01659-2.
PMID: 35928075
18
Margin status revisited in vulvar squamous cell carcinoma.
Te Grootenhuis NC, Pouwer AW, de Bock GH, et al.
Gynecologic oncology 2019; (154(2)):266-275 doi:10.1016/j.ygyno.2019.05.010.
PMID: 31109660
19
Combination of surgery and laser for the treatment of extensive VIN3 and vulval condyloma: A case report.
Farzaneh F, Khalili L, Rakhshani N, et al.
Annals of medicine and surgery (2012) 2022; (78()):103763 doi:10.1016/j.amsu.2022.103763.
PMID: 35734690

This page explains the two biological pathways of VIN for educational purposes only. Always consult your gynecologist or oncologist for an accurate interpretation of your specific pathology report and treatment plan.

Get notified when new evidence is published on Vulvar intraepithelial neoplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents